Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

Home >> Signaling Pathways >> Tyrosine Kinase >> EGFR

EGFR

EGFR (epidermal growth factor receptor) is the cell-surface receptor of its specific ligands, including epidermal growth factor and TGFα (transforming growth factor α) and is a receptor tyrosine kinase.

  1. Cat.No. Product Name Information
  2. GC38006 β-Hydroxyisovalerylshikonin Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermium radix, acts as a potent inhibitor of protein tyrosine kinases (PTK), with IC50s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells. β-Hydroxyisovalerylshikonin Chemical Structure
  3. GC61807 (E/Z)-AG490 (E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3. (E/Z)-AG490 Chemical Structure
  4. GC63797 (S)-Sunvozertinib (S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against EGFR exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC50=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK. (S)-Sunvozertinib Chemical Structure
  5. GC12818 4-methyl Erlotinib EGFR inhibitor 4-methyl Erlotinib Chemical Structure
  6. GC13257 AC480 (BMS-599626) AC480 (BMS-599626) (AC480) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC50s of 20 and 30 nM, respectively. AC480 (BMS-599626) displays ~8-fold less potent to HER4 (IC50=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. AC480 (BMS-599626) inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy. AC480 (BMS-599626) Chemical Structure
  7. GC11892 AEE788 (NVP-AEE788) AEE788 (NVP-AEE788) is an inhibitor of the EGFR and ErbB2 with IC50 values of 2 and 6 nM, respectively. AEE788 (NVP-AEE788) Chemical Structure
  8. GC10707 Afatinib dimaleate

    EGFR inhibitor

     Afatinib dimaleate Chemical Structure
  9. GC60567 Afatinib impurity 11 Afatinib impurity 11 is an impurity of Afatinib. Afatinib is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib impurity 11 Chemical Structure
  10. GC13296 Afatinib(BIBW2992) Irreversible EGFR/HER2 inhibitor Afatinib(BIBW2992) Chemical Structure
  11. GC50013 AG 1478 hydrochloride Highly potent EGFR-kinase inhibitor AG 1478 hydrochloride Chemical Structure
  12. GC17489 AG 494 Potent EGFR-kinase inhibitor AG 494 Chemical Structure
  13. GC11744 AG 555 Potent EGFR-kinase inhibitor AG 555 Chemical Structure
  14. GC12233 AG 556 AG 556 is a highly selective EGFR inhibitor and also blocks LPS-induced TNF-α production. AG 556 Chemical Structure
  15. GC13168 AG 825 Selective ErbB2 inhibitor AG 825 Chemical Structure
  16. GC14494 AG 99 AG 99 ((E)-Tyrphostin 46) is a potent EGFR inhibitor. AG 99 Chemical Structure
  17. GC17226 AG-1478 EGFR inhibitor,potent and selective AG-1478 Chemical Structure
  18. GC12864 AG-1557 inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase AG-1557 Chemical Structure
  19. GC17647 AG-18 AG-18 (Tyrphostin A23) is an EGFR inhibitor with an IC50 and Kiof 35 and 11 μM, respectively. AG-18 Chemical Structure
  20. GC14890 AG-183 AG-183 is the Z configuration of Lanoconazole A51. AG-183 Chemical Structure
  21. GC11024 AG-213 inhibitor of epidermal growth factor (EGF) receptor kinase AG-213 Chemical Structure
  22. GC13854 AG-490 (Tyrphostin B42) AG-490 (Tyrphostin B42) (Tyrphostin AG-490 (Tyrphostin B42)) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3. AG-490 (Tyrphostin B42) Chemical Structure
  23. GC11845 AG-82 AG-82 (AG82) is a specific inhibitor of the EGFR tyrosine kinase. AG-82 Chemical Structure
  24. GC64398 Almonertinib mesylate Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer. Almonertinib mesylate Chemical Structure
  25. GC67749 Amivantamab Amivantamab Chemical Structure
  26. GC17283 AP26113 AP26113 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1. AP26113 Chemical Structure
  27. GC12478 ARRY-380 ARRY-380, an inhibitor of EGFR (ErbB1), is extracted from patent WO2015153959A2, compound 249. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2. ARRY-380 Chemical Structure
  28. GC62402 ASK120067 ASK120067 (ASK120067) is a potent and orally active inhibitor of EGFRT790M (IC50:0.3 nM) with selectivity over EGFRWT (IC50:6.0 nM). ASK120067 is a third-generation EGFR-TKI for the research ofnon-small cell lung cancer (NSCLC). ASK120067 Chemical Structure
  29. GC11691 AST-1306 AST-1306 (AST-1306) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. AST-1306 also inhibits ErbB4 with an IC50 of 0.8 nM. AST-1306 is an anilino-quinazoline compound and has anti-cancer activity. AST-1306 Chemical Structure
  30. GC15669 AST-1306 TsOH AST-1306 TsOH (AST-1306 (TsOH)) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. AST-1306 TsOH also inhibits ErbB4 with an IC50 of 0.8 nM. AST-1306 TsOH is an anilino-quinazoline compound and has anti-cancer activity AST-1306 TsOH Chemical Structure
  31. GC33096 AST2818 mesylate Alflutinib (Furmonertinib) mesylate is is a potent inhibitor of EGFR. Alflutinib (Furmonertinib) mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib (Furmonertinib) mesylate has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC). AST2818 mesylate Chemical Structure
  32. GC62481 AST5902 trimesylate AST5902 trimesylate is the principal metabolite of Alflutinib (AST2818) both in vitro and in vivo. AST5902 trimesylate exerts antineoplastic activity. Alflutinib is an EGFR inhibitor. AST5902 trimesylate Chemical Structure
  33. GC35413 Astragaloside VI Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing. Astragaloside VI Chemical Structure
  34. GC35435 AV-412 A dual inhibitor of EGFR and HER2 AV-412 Chemical Structure
  35. GC35436 AV-412 free base AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively. AV-412 free base Chemical Structure
  36. GC19044 Avitinib maleate

    A pyrrolopyrimidine-based irreversible EGFR inhibitor

     Avitinib maleate Chemical Structure
  37. GC12955 AZ5104 EGFR inhibitor AZ5104 Chemical Structure
  38. GC16308 AZD-9291 AZD-9291 (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. AZD-9291 overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. AZD-9291 Chemical Structure
  39. GC16698 AZD-9291 mesylate AZD-9291 mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. AZD-9291 mesylate Chemical Structure
  40. GC13143 AZD3759 AZD3759 (AZD3759) is a potent, orally active, central nervous system-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.3, 0.2, and 0.2 nM for EGFRwt, EGFRL858R, and EGFRexon 19Del, respectively. AZD3759 Chemical Structure
  41. GC13761 AZD8931 (Sapitinib) AZD8931 (Sapitinib) (AZD-8931) is a reversible, ATP competitive EGFR inhibitor of with IC50s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively. AZD8931 (Sapitinib) Chemical Structure
  42. GC64302 BAY 2476568 BAY 2476568 is a potent and selective EGFR inhibitor, with IC50s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG). BAY 2476568 Chemical Structure
  43. GC64017 Befotertinib Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC). Befotertinib Chemical Structure
  44. GC33172 BGB-102 (JNJ-26483327) BGB-102 (JNJ-26483327) is a potent multi-kinase inhibitor against EGFR, HER2, and HER4 with IC50s of 9.6 nM, 18 nM and 40.3 nM, respectively. BGB-102 (JNJ-26483327) Chemical Structure
  45. GC19066 BGB-283 BGB-283 is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively. BGB-283 Chemical Structure
  46. GC38402 BI-4020 A fourth-generation and non-covalent EGFR tyrosine kinase inhibitor BI-4020 Chemical Structure
  47. GC10815 BIBU 1361 dihydrochloride EGFR inhibitor BIBU 1361 dihydrochloride Chemical Structure
  48. GC10087 BIBX 1382 BIBX 1382 (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. BIBX 1382 displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM). BIBX 1382 is a pyrimido-pyrimidine compound and has anti-cancer activity. BIBX 1382 Chemical Structure
  49. GC50026 BIBX 1382 dihydrochloride Highly selective EGFR-kinase inhibitor BIBX 1382 dihydrochloride Chemical Structure
  50. GC63910 BLU-945 BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC). BLU-945 Chemical Structure
  51. GC14136 BMS 599626 dihydrochloride EGFR and ErbB2 inhibitor,potent and selective BMS 599626 dihydrochloride Chemical Structure
  52. GC10606 BMS-599626 Hydrochloride EGFR/HER2 inhibitor,potent and selective BMS-599626 Hydrochloride Chemical Structure
  53. GC13873 BMS-690514 HER/EGFR inhibitor BMS-690514 Chemical Structure
  54. GC10944 Butein Protein kinase inhibitor Butein Chemical Structure
  55. GC12910 Canertinib (CI-1033) Canertinib (CI-1033) (CI-1033;PD-183805) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. Canertinib (CI-1033) Chemical Structure
  56. GC12087 Canertinib dihydrochloride Pan-ErbB inhibitor, potent and selective Canertinib dihydrochloride Chemical Structure
  57. GC34217 Cetuximab (C225) Cetuximab (C225) (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab (C225) has potent antitumor activity. Cetuximab (C225) Chemical Structure
  58. GC15950 CGP 52411 EGFR inhibitor CGP 52411 Chemical Structure
  59. GC25219 CH7233163 CH7233163 is a non-covalent ATP competitive inhibitor of EGFR-tyrosine kinase with antitumor activities against tumor with EGFR-Del19/T790M/C797S. CH7233163 Chemical Structure
  60. GC35684 CHMFL-EGFR-202 CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. CHMFL-EGFR-202 exhibits ?10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 adopts a covalent “DFG-in-C-helix-out” inactive binding conformation with EGFR, with strong antiproliferative effects against EGFR mutant-driven nonsmall-cell lung cancer (NSCLC) cell lines. CHMFL-EGFR-202 Chemical Structure
  61. GN10327 Chrysophanol

    Extracted from Rheum palmatum L.;Suitability:Boiling ethanol,benzene,chloroform,ether,acetic acid and acetone;Store the product in sealed,cool and dry condition

     Chrysophanol Chemical Structure
  62. GC17790 CL-387785 (EKI-785) CL-387785 (EKI-785)(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC50 of 370 pM. CL-387785 (EKI-785) Chemical Structure
  63. GC11264 CNX-2006

    mutant-EGFR inhibitor, selective and irreversible

     CNX-2006 Chemical Structure
  64. GC14695 CO-1686 (AVL-301) CO-1686 (AVL-301) (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively. CO-1686 (AVL-301) Chemical Structure
  65. GC12837 Compound 56

    REGFR inhibitor

     Compound 56 Chemical Structure
  66. GC13091 CP-724714 HER2 inhibitor,potent and selective CP-724714 Chemical Structure
  67. GC16008 CUDC-101

    Multitargeted HDAC inhibitor

     CUDC-101 Chemical Structure
  68. GC38180 Cyasterone Cyasterone Chemical Structure
  69. GC10225 Dacomitinib (PF299804, PF299) Dacomitinib (PF299804, PF299) (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively. Dacomitinib (PF299804, PF299) Chemical Structure
  70. GN10336 Daphnetin Protein kinases inhibitor for EGFR/PKA/PKC Daphnetin Chemical Structure
  71. GC62569 DBPR112 DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy. DBPR112 Chemical Structure
  72. GC64039 Disitamab vedotin Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity. Disitamab vedotin Chemical Structure
  73. GC66432 EAI001 EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer. EAI001 Chemical Structure
  74. GC12281 EAI045 Inhibitor of L858R/T790M EGFR mutants EAI045 Chemical Structure
  75. GC16321 EGF816 EGF816 (EGF816) is a covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min-1 on EGFR(L858R/790M) mutant, respectively. EGF816 Chemical Structure
  76. GC11312 EGFR Inhibitor EGFR Inhibitor is a 4,6-disubstituted pyrimidine and is a potent, ATP-competitive, irreversible and highly selective EGFR inhibitor with an IC50of 21 nM. EGFR Inhibitor also inhibits mutant EGFRL858R and EGFRL861Q with IC50s of 63 nM and 4 nM, respectively. EGFR Inhibitor displays strong selectivity for EGFR over HER4 (IC50 = 7640 nM) and a panel of 55 other kinases. EGFR Inhibitor induces cells apoptosis and has antitumor activity. EGFR Inhibitor Chemical Structure
  77. GC35965 EGFR mutant-IN-1 EGFR mutant-IN-1, a 5-methylpyrimidopyridone derivative, is a potent and selective EGFRL858R/T790M/C797S mutant inhibitor with an IC50 of 27.5 nM, while being a significantly less potent for EGFRWT (IC50 >1.0 μM). EGFR mutant-IN-1 Chemical Structure
  78. GC65572 EGFR Protein Tyrosine Kinase Substrate EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate. EGFR Protein Tyrosine Kinase Substrate Chemical Structure
  79. GC62562 EGFR-IN-11 EGFR-IN-11 is a fourth-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) with an IC50 of 18 nM for triple mutant EGFRL858R/T790M/C797S. EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1. EGFR-IN-11 Chemical Structure
  80. GC64497 EGFR-IN-17 EGFR-IN-17 is a potent and selective inhibitor of the epidermal growth factor receptor ( IC50 0.0002 μM) to overcome C797S-mediated resistance. EGFR-IN-17 Chemical Structure
  81. GC33195 EGFR-IN-2 EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor. EGFR-IN-2 Chemical Structure
  82. GC19132 EGFR-IN-3 EGFR-IN-3 is a third-generation EGFR TKI, with GI50 values of 5 nM (EGFR L858R/T790M), 10 nM (EGFR del19) and 689 nM (EGFR WT), respectively. EGFR-IN-3 has the potential for NSCLC research. EGFR-IN-3 Chemical Structure
  83. GC66428 EGFR-IN-5 EGFR-IN-5 is a EGFR inhibitor with IC50s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFRL858R, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively. EGFR-IN-5 Chemical Structure
  84. GC35966 EGFR-IN-7 EGFR-IN-7 is a potent, selective and orally active EGFR kinase inhibitor. EGFR-IN-7 has inhibitory effect for for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) with IC50 values of 7.92 nM and 0.218 nM, respectively. EGFR-IN-7 shows anti-tumor activity. EGFR-IN-7 can be used for the research of various cancers. EGFR-IN-7 Chemical Structure
  85. GC65974 EGFR-IN-9 EGFR-IN-9 (Compound 8) is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity. EGFR-IN-9 Chemical Structure
  86. GC14856 EGFR/ErbB2 Inhibitor EGFR/ErbB2 Inhibitor (Compound 5) is a EGFR and ErbB inhibitor with IC50s of 0.017 μM, 0.08 μM, 1.91 μM. EGFR/ErbB2 Inhibitor Chemical Structure
  87. GC60805 EMI48 EMI48, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI48 inhibits EGFR triple mutants. EMI48 Chemical Structure
  88. GC62420 EMI56 EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants. EMI56 Chemical Structure
  89. GC33048 Epertinib (S-22611) Epertinib (S-22611) (S-22611) is a potent, oral, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib (S-22611) shows potent antitumor activity. Epertinib (S-22611) Chemical Structure
  90. GC38350 Epertinib hydrochloride Epertinib hydrochloride (S-22611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride shows potent antitumor activity. Epertinib hydrochloride Chemical Structure
  91. GC62384 Epitinib succinate Epitinib succinate is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib succinate can be used for the research of cancer. Epitinib succinate Chemical Structure
  92. GC10627 Erlotinib EGFR tyrosine kinase inhibitor Erlotinib Chemical Structure
  93. GC60154 Erlotinib D6 Erlotinib D6 (CP-358774 D6) is a deuterium labeled Erlotinib (CP-358774). Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR. Erlotinib D6 Chemical Structure
  94. GC15600 Erlotinib Hydrochloride Selective EGFR inhibitor Erlotinib Hydrochloride Chemical Structure
  95. GC36003 Erlotinib mesylate EGFR inhibitor Erlotinib mesylate Chemical Structure
  96. GC62958 Erlotinib-13C6 Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib-13C6 Chemical Structure
  97. GC47303 Erlotinib-d6 (hydrochloride) An internal standard for the quantification of erlotinib Erlotinib-d6 (hydrochloride) Chemical Structure
  98. GC65992 FGFR2-IN-3 FGFR2-IN-3 is an orally active selective inhibitor of FGFR2. FGFR2-IN-3 Chemical Structure
  99. GC65991 FGFR2-IN-3 hydrochloride FGFR2-IN-3 hydrochloride is an orally active selective inhibitor of FGFR2. FGFR2-IN-3 hydrochloride Chemical Structure
  100. GC17323 FIIN-2 Irreversible inhibitor of FGFR FIIN-2 Chemical Structure
  101. GC36044 FIIN-3 FIIN-3 is an irreversible inhibitor of FGFR with an IC50 of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FIIN-3 Chemical Structure

Items 1 to 100 of 197 total

per page
  1. 1
  2. 2

Set Descending Direction